New Study Lends Evidence to Link Between Use of Bisphosphonates and Femur Fractures, More Fosamax Lawsuits Filed
Research recently published in the Journal of Bone and Joint Surgery may be strengthening the possibility that use of bisphosphonates can lead to non-healing femoral fractures, a causative relationship that has already prompted thousands of patients to file Fosamax lawsuits.
U.S. scientists in this study counted 362 reports of non-healing femoral fractures in the U.S. Food and Drug Agency Adverse Event Reporting System (FAERS) database, according to a Mar. 1 report from News-Medical.net. The ratio for these fractures and use of bisphosphonates, like bone-loss drug Fosamax, was 4.51.
The investigation found that 26% of atypical femoral fractures were non-healing. This may suggest that “some of the nonhealing femoral fractures in the FAERS database could well be atypical femoral fractures,” they said.
Fosamax Lawsuits Naming Atypical Femur Fractures On the Rise
An atypical femur fracture is a particularly unusual injury since the femur is one of the strongest bones in the body, and thus the hardest to break. However, more and more Fosamax lawyers are naming it in the lawsuits they filed on behalf of patients, Ring of Fire radio reported in February 2013.
Given the rising number of claims filed against Merck & Co., a second federal multidistrict litigation has been established in the U.S. District Court, District of New Jersey to handle lawsuits alleging atypical femur fractures stemming from use of the bone-loss drug. The first federal MDL handling Fosamax lawsuits was created in November 2011 to consolidate the 1,500 claims that had been filed by patients who claim to have suffered osteonecrosis of the jaw (ONJ) after taking the medication.
As a conclusion to the research published in the Journal of Bone and Joint Surgery, the team concluded its literature review with a call for an international registry to keep track of atypical femoral fractures related to bisphosphonates, and for further investigation of underlying genetic susceptibility of femoral fractures, and developing fractures in the clinic.
“A better understanding of the mechanisms leading to these atypical femoral fractures may enable us to develop prediction rules for this uncommon adverse drug reaction and to stratify and target our care accordingly,” researchers said.
Considering a Lawsuit? Call a Fosamax Lawyer Today.
If you suffered an atypical femur fracture after taking Fosamax, you may be eligible to file a claim against Merck & Co. Contact a Fosamax lawyer at Bernstein Liebhard LLP by calling (877) 779-1414 to learn more about Fosamax lawsuits.